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Ghrelin, a stomach-derived peptide, stimulates feeding behavior and adiposity. For its orexigenic
action, ghrelin triggers a central SIRT1/p53/AMPK pathway. The tumor suppressor p53 also plays
an important role in white adipose tissue (WAT), where it is up-regulated in the adipocytes of obese
mice. It is not known, however, whether p53 has any role in mediating the peripheral action of
ghrelin. In the present study, chronic peripheral ghrelin treatment resulted in increased body
weight and fat-mass gain in wild-type mice. Correspondingly, mRNA levels of several adipogenic
and fat-storage-promoting enzymes were up-regulated in WAT, whereas hepatic triglyceride con-
tent and lipogenic enzymes were also increased in wild-type mice following ghrelin treatment. In
contrast,mice lackingp53failedtorespondtoghrelin treatment,withtheirbodyweight, fatmass,and
adipocyte and hepatic metabolism remaining unchanged. Thus, our results show that p53 is necessary
for the actions of ghrelin on WAT and liver, leading to changes in expression levels of lipogenic and
adipogenic genes, and modifying body weight. (Endocrinology 154: 3671–3679, 2013)
Ghrelin is the only known endogenous peptidic hor-mone that stimulates feeding (1) and adiposity (2–4).
An increase in fat mass is observed after ghrelin infusion,
either centrally (3, 5) or peripherally (2). Correspond-
ingly, ghrelin ameliorates cachexia due to a range of
pathophysiological conditions like cancer or anorexia ner-
vosa, in both humans and animal models (6–9). Although
the mechanisms responsible are far from being under-
stood, in vitro studies demonstrate that ghrelin stimulates
the differentiation of rat preadipocytes, antagonizes iso-
proterenol-induced lipolysis (10) and stimulates lipid ac-
cumulation as well as TNF-induced apoptosis in human
visceral adipocytes (11, 12). In addition to its direct ac-
tions on white adipose tissue (WAT), chronic systemic
infusion of ghrelin induces hepatic steatosis, increasing
lipid droplet number and triacylglycerol content by a
growth-hormone-secretagogue-receptor-1a (GHS-R1a)-
dependent mechanism (13). Similarly, chronic central in-
fusion of ghrelin also favors hepatic lipid storage and re-
duces lipid mobilization (5). Notably, the anabolic effects
of ghrelin are, at least partially, independent of its hy-
perphagic effect. For instance, chronic central infusion of
ghrelin in diet-induced obese (DIO) rats increases adipos-
ity and gene expression of lipogenic enzymes in WAT even
though food intake remains unchanged (14), due to DIO
ghrelin resistance in arcuate NPY/AgRP neurons (15).
p53 is a tumor suppressor gene that, in addition to its
biological actions in cancer, plays an important role in
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several metabolically relevant tissues including adipose
tissue (16). p53 is highly induced in white adipocytes of
leptin-deficient mice (17) and of DIO mice (18). Disrup-
tion of p53 in leptin-deficient mice can partially restore
expression of lipogenic enzymes, whereas p53 overexpres-
sion suppresses expression of lipogenic genes, suggesting
that activation of p53 decreases fat storage in adipocytes
(17). p53 expression in WAT is also crucially involved in
the development of insulin resistance, as demonstrated by
the fact that inhibition of p53 activity in WAT markedly
improves insulin sensitivity in mice (18, 19). Conversely,
up-regulation of p53 in adipose tissue causes an inflam-
matory response that leads to insulin resistance (18).
In addition to its functions in adipocyte metabolism,
central p53 also plays an important metabolic role in me-
diating ghrelin-induced food intake (20). In the present
study, we therefore aimed to determine whether p53 is
essential for the peripheral actions of ghrelin on lipid me-
tabolism in WAT and liver.
Materials and Methods
Animal models
p53-null (8–10 wk old, males and females, mixed back-
ground C57BL/6J and 129/Sv) mice were used, as previously
described (21). Homozygous wild-type (WT) and knockout
(KO) mice were derived from heterozygous matings, and in each
experiment only littermate WT and KO animals were compared.
Animals were kept on a 12-hour light, 12-hour dark cycle, at
22°C, with free access to tap water. Animals were treated and
killed before any sign of morbidity due to tumor development
occurred. Animals were killed by decapitation between 10:00
and 12:00 hours. Animal experiments were conducted in ac-
cordance with the standards approved by the Faculty Animal
Committee at the University of Santiago de Compostela, and
in agreement with the Rules of Laboratory Animal Care and
International Law on Animal Experimentation.
Chronic ghrelin treatment
We peripherally administered ghrelin during a 1-week period
(30 g/d, daily ip injection at 9 AM) to WT and p53-null mice (n 
7–8 per group). Food intake, body weight, body composition,
and adipocyte and hepatic metabolism were assessed. Body com-
position was measured in injected mice using nuclear magnetic
resonance (Whole Body Composition Analyzer; EchoMRI,
Houston, Texas), both before ghrelin treatment and following
the treatment period but before killing. On day 7, 2 hours after
the last injection, mice were killed and tissues were collected and
frozen at 80°C until further analysis.
Quantitative RT-PCR
RNA was extracted using Trizol reagent (Invitrogen, Carls-
bad, California) according to the manufacturer’s instructions.
Two micrograms of total RNA was used for each RT reaction,
and cDNA synthesis was performed using the SuperScript First-
Strand Synthesis System (Invitrogen) and random primers as pre-
viously described (22). Negative control reactions, containing all
reagents except the sample, were used to ensure specificity of the
PCR amplification. For analysis of gene expression, we per-
formed real-time RT-PCR assays using a fluorescent tempera-
ture cycler (TaqMan; Applied Biosystems, Foster City, Califor-
nia) following the manufacturer’s instructions (22, 23). For each
RT reaction, 500 ng total RNA was used. The PCR cycling con-
ditions included an initial denaturation at 50°C for 10 minutes
followed by 40 cycles at 95°C for 15 seconds and 60°C for 1
minute. The oligonucleotide-specific primers are shown in Sup-
plemental Table 1, published on The Endocrine Society’s Jour-
nals Online web site at http://endo.endojournals.org. For anal-
ysis of the data, the input value of gene expression was
standardized to the 18S value for the sample group and expressed
as a comparison with the average value for the control group.
Hepatic triglyceride content
The extraction procedure for tissue triglyceride (TG) was
adapted from methods described previously (24). Liver tissue
(approximately 200 mg) was homogenized for 2 minutes in ice-
cold chloroform-methanol (2:1 vol:vol). Initial extraction of TG
was carried out by 5-hour shaking at room temperature. For
phase separation, H2SO4 was added; samples were centrifuged,
and the organic lower layer was collected. The solvent was dried
using a Speed Vac and the organic residue was redissolved in
chloroform. TG content of each sample was measured in dupli-
cate after evaporation of the organic solvent using an enzymatic
method (Randox Laboratories Ltd, Crumlin, United Kingdom).
Effect of ghrelin on adipose tissue explants
Perigonadal adipose tissue explants were prepared by cutting
samples into 5-mg portions, which were subsequently incubated
for 30 minutes in PBS supplemented with 2% BSA. After a brief
centrifugation (400g, 30 s), samples were incubated in adipocyte
medium (DMEM/F12 [1:1]; Gibco, Invitrogen, Carlsbad, Cali-
fornia) containing 17.5 mM glucose, 121 mM NaCl, 4 mM KCl,
1 mM CaCl2, 25 mM HEPES, 2.4 mM sodium bicarbonate, 2%
BSA, 8 mM biotin, 18 mM panthotenate, 100 mM ascorbate and
antibiotic-antimycotic) for 1 hour at 37°C. Thereafter, 108 M
ghrelin was added (25) and tissue explants were incubated for
either 5 minutes (for the analysis of the phosphorylation rate of
ERK and AMP-activated protein kinase [AMPK]) or 12 or 24
hours (for gene expression measurements) at 37°C. At the end of
the experimental treatments, tissue explants were collected,
washed, and processed for RNA or protein extraction as indi-
cated below.
Western blotting
Western blotting was performed as previously described (20,
26). Briefly, total protein lysates from liver (20 g) were sub-
jected to SDS-PAGE, electrotransferred onto a polyvinylidene
difluoride membrane, and probed with the following antibodies:
ACC, phospho-ACC-Ser79 (pACC), AMPK1 and AMPK2
(Upstate, Lake Placid, New York); phospho-AMPK-Thr172
(pAMPK; Cell Signaling, Danvers, Massachusetts); phospho-
p44/42 MAPK (Erk1/2) (Thr202/Tyr204) and Erk1/2 were from
Cell Signaling Technology, Inc (Danvers, Massachusetts); -ac-
tin (Sigma-Aldrich, St Louis, Missouri); CPT1, FAS (H-300), and
LPL (H-53) (Santa Cruz Biotechnology, Santa Cruz, California).
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For protein detection, we used horseradish peroxidase–conju-
gated secondary antibodies (Dako, Glostrup, Denmark) and
chemiluminescence (Pierce ECL Western Blotting Substrate;
Thermo Scientific, Rockford, Illinois). Membranes were then
exposed to X-ray film (Super RX, Fuji Medical X-Ray Film;
Fujifilm, Tokyo, Japan) and developed with developer and fixing
liquids (AGFA, Mortsel, Belgium) under appropriate dark-room
conditions. Protein levels were normalized to -actin for each
sample.
Levels of serum metabolites and hormones
Serum free-fatty-acid concentrations were determined using a
kit from Wako (Richmond, Virginia); TG and cholesterol were
determined using kits from Randox Laboratories Ltd. Serum
insulin levels were measured using a previously described RIA
technique (27). Glucose levels were measured an Accucheck glu-
cometer (Roche, Indianapolis, Indiana) and serum corticoste-
rone levels were measured using a corticosterone ELISA kit
(Enzo Life Sciences, Telluride, Colorado) following manufac-
tured instructions.
Data analysis and statistical tests
Values were plotted as the mean  SEM for each genotype.
Seven to eight animals per group were used for all analyses.
Statistical analysis was performed using a two-way ANOVA
followed by a Bonferroni’s post test. R version 2.15.1. was used
for data analysis. A P value less than .05 was considered statis-
tically significant.
Results
Lack of p53 blunts chronic ghrelin-induced gains in
body weight and fat mass
To assess the relevance of p53 for the action of chronic
ghrelin on body weight and adiposity, we treated WT and
p53 KO mice with ghrelin (30 g/day, daily ip) for 1 week.
This chronic peripheral ghrelin treatment did not modify
food intake in either WT mice or mice lacking p53 (Figure
1A). Chronically administered ghrelin led to an increase in
percentage body weight in WT mice, although a two-way
ANOVA failed to give a significant interaction between
ghrelin and p53 (P  .25, F  1.31, df  1) (Figure 1B).
However, if an unpaired t test is used to compare only
saline-treated vs ghrelin-treated WT animals, the differ-
ence was statistically significant (P  .05). In mice lacking
p53 ghrelin failed to cause any change in body weight
Figure 1. Effect of a 7-day ip ghrelin injection (30 g/d) on cumulative food intake (A), percentage of body weight gain (B), percentage of total
fat mass (C), and percentage of total nonfat mass (D) in WT and p53 KO mice. Values are mean  SEM of 7–8 animals per group. Two-way
ANOVA was used as statistical test.
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(Figure 1B). The increased body weight in ghrelin-treated
WT mice was consistent with a gain in percentage fat mass,
although again, there was not an interaction between
ghrelin and p53 (P  .07, F  3.38, df  1) (Figure 1C),
but an unpaired t test comparing only saline-treated vs
ghrelin-treated WT animals showed significant differ-
ences. Fat mass was unchanged between vehicle-treated
and ghrelin-treated p53 KO mice (Figure 1C). Finally, we
did not observe changes in the percentage of lean mass
after chronic peripheral ghrelin treatment in either WT or
p53 KO mice (Figure 1D). Importantly, the body weight,
food intake, and body composition was very similar be-
tween WT and p53-deficient mice before starting the ghre-
lin treatment (Table 1). Chronic treatment with ghrelin
was associated with a positive energy balance without any
significant effects on serum glucose, insulin, TG, choles-
terol, free fatty acid, or corticosterone levels (Table 2).
Lack of p53 blocks the lipogenic effect of chronic
ghrelin in WAT
We next assessed the expression of several key enzymes
involved in the regulation of lipid metabolism in WAT. A
two-way ANOVA showed that there was an interaction
between ghrelin treatment and the lack of p53 for the
following genes: sterol regulatory element binding protein
1c (SREBP1c) (P  .0014, F  13.54, df  1), fatty acid
synthase (FAS) (P  .0106, F  7.80, df  1), lipoprotein
lipase (LPL) (P  .002, F  11.46, df  1), and CCAAT/
enhancer-binding protein  (CEBP) (P  .033, F  5.16,
df  1). In these genes, we then performed a Bonferroni’s
post test as represented in Figure 2A. WT mice chronically
treated with ip ghrelin showed a significant increase in
gene expression of enzymes involved in de novo synthesis
of fatty acids such as SREBP1c and FAS (Figure 2A). Ghre-
lin treatment also stimulated expression of LPL, which
favors lipid uptake, in the WAT of WT mice (Figure 2A).
In addition, we found a significant up-regulation in WAT
mRNA levels of CEBP, which activates adipogenesis, in
WT mice treated with ghrelin (Figure 2A). In sharp con-
trast to these changes found in WT WAT, we failed to
detect any significant changes in mRNA expression for the
same enzymes in the WAT of p53 KO mice, following
chronic ghrelin treatment (Figure 2A). These results there-
fore indicate that p53 is essential for the adipogenic action
of ghrelin in WAT. To note, a significant increase between
WT and p53-deficient mice was found in the WAT ex-
pression of LPL and SREBP1 (Figure 2A).
To test if ghrelin could modulate adipocyte metabolism
directly, we incubated adipose tissue explants with saline
or ghrelin (108 M). In our in vitro experiments we first
confirmed the efficiency of ghrelin treatment by evaluating
its ability to activate ERK and AMPK at the short term. We
found that, as expected, ghrelin did increase ERK and
AMPK phosphorylation rate in the samples (Figure 2B).
Because our in vivo experiments represented a chronic
treatment with ghrelin, we next examined the expression
of genes involved in lipid metabolism and adipogenesis in
the adipose tissue explants of WT mice after long-term
incubation with saline or vehicle. After 12 or 24 hours,
ghrelin did not cause any significant change in the expres-
sion levels of any of the genes examined when directly
administered to adipose tissue explants, with the excep-
tion of ACC that was decreased after 24 hours of expo-
sure to the peptide (Figure 2, C and D) Thus, these findings
indicate that the chronic effect of ghrelin on adipose tissue
metabolism is not direct.
Lack of p53 blocks the lipogenic effect of ghrelin
in liver
Next, we investigated whether the lack of p53 was
modulating the effects of ghrelin specifically in WAT, or
whether it was also relevant to ghrelin’s action on another
Table 1. Body Weight (BW), Fat Mass, and Lean Mass
of WT and p53-deficient Mice (KO) in Untreated Animals
Fed a Standard Diet
WT P53 KO
BW, g 22.11  1.18 20.59  0.98
Fat mass, g 1.88  0.09 1.98  0.09
Lean mass, g 18.92  0.93 17.67  0.89
Fat mass, % 8.5  0.34 9.67  0.47
Lean mass, % 85.16  1.4 85.11  0.77
Table 2. Circulating Levels of Nonesterified Fatty Acids (NEFAs), TG, Cholesterol, Glucose, Insulin, and
Corticosterone in WT and p53 KO Mice, in Chronically Ghrelin-treated (GHR) and Control (SAL) Groups (7–8 animals
per group)
WT-SAL WT-GHR KO-SAL KO-GHR
NEFAs, mg/dL 39.42  5.66 31.37  2.59 31.37  2.59 25.78  2.65
TG, mg/dL 7.00  0.77 6.5  0.37 5.1  0.40 5.67  0.73
Cholesterol, mg/dL 16.81  0.86 20.68  1.53 16.77  0.83 18.50  1.16
Glucose, mg/dL 14.85  1.32 12.52  1,08 13.08  0.57 14.03  0.49
Insulin, ng/mL 0.66  0.15 0.73  0.11 0.46  0.08 0.56  0.05
Corticoesterone, ng/mL 5.51  1.12 5.76  1.35 5.27  1.49 5.36  0.75
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peripheral metabolic tissue, the liver. We found that
chronic peripheral treatment with ghrelin increased he-
patic TG content in WT but not in p53-deficient mice
(Figure 3A). To dissect the molecular underpinnings of the
increased content of hepatic TG in ghrelin-treated WT
mice further, we analyzed the expression profile of key
enzymes involved in liver lipid metabolism. First, we
found a significant interaction between ghrelin treatment
and the lack of p53 for the hepatic levels of ACC (P 
.0005, F  17, df  1) and FAS (P  .017, F  6.53, df 
1). In these 2 genes, we then performed a Bonferroni’s post
test as represented in Figure 3C. Chronic ip ghrelin mark-
Figure 2. Effects of a 7-day ip ghrelin injection (30 g/d) on epididymal WAT mRNA expression of SREBP1c, acetyl CoA carboxylase  (ACC),
LPL, insulin-induced gene 2 (INSIG2), peroxisome proliferator-activated receptor  (PPAR), CEBP, and FAS, in WT and p53 KO mice (A). On day
7, 2 hours after the last injection, mice were killed and tissues were collected and frozen at 80°C until further analysis. Values are mean  SEM
of 7 to 8 animals per group. Two-way ANOVA followed by a Bonferroni’s post test was used as statistical test. Effect of ghrelin (108 M) on WT
mice adipose tissue explants on pAMPK, AMPK, pERK, ERK levels (n  3) (B) and SREBP1c, ACC, LPL, PPAR, CEBP, and FAS mRNA expression
after 12 hours (n  6) (C) and 24 hours (n  6) (D). *, P  .05; **, P  .01.
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edly increased hepatic protein levels of enzymes favoring
lipid synthesis, namely ACC and FAS, in WT mice (Fig-
ure 3, B and C), whereas the peptide had no effect on
enzymes promoting fatty acid oxidation such as CPT-1.
This was not the case, however, in p53-deficient mice,
which did not show any significant changes in any of the
proteins studied (Figure 3, B and C). Overall, these results
suggest that p53 also plays a relevant role in the lipogenic
action of ghrelin in the liver. To note, hepatic levels of TG,
ACC, and FAS were significantly increased in p53-defi-
cient mice in comparison to WT mice, indicating that the
lack of this gene causes hepatic alterations in lipid
metabolism.
Lack of p53 blocks the hypothalamic action of
ghrelin on lipid metabolism
Because it is well known that short-term (2–6 h) ghrelin
modulates hypothalamic AMPK-fatty acid metabolism
(28, 29) through the SIRT1-p53 pathway (20), we finally
assessed if the chronic peripheral injection of ghrelin was
affecting hypothalamic lipid metabolism. We found a sig-
nificant interaction between ghrelin treatment and the
lack of p53 for the hypothalamic levels of ACC (P  .02,
F  6.30, df  1) and FAS (P  .03, F  5.11, df  1). In
these 2 genes, we then performed a Bonferroni’s post test
as represented in Figure 3C. We found that chronic pe-
ripheral treatment with ghrelin decreased the hypotha-
lamic protein levels of ACC and FAS in WT mice, but not
in ghrelin-treated p53-deficient mice (Figure 4). Although
it was reported that acute central infusion of ghrelin in-
creased hypothalamic pAMPK levels (28, 29), in our study
we failed to detect significant changes in hypothalamic
pAMPK levels after the chronic peripheral injections as
reported in previous studies (30), indicating that phopho-
rylation of this enzyme by ghrelin is time-dependent.
Figure 3. Effect of a 7-day ip ghrelin injection (30 g/d) on hepatic TG content (A), and hepatic protein levels of phosphorylated AMP-activated
protein kinase (pAMPK), AMPK1, AMPK2, phosphorylated acetyl CoA carboxylase (pACC), carnitine palmitoyltransferase-1 (CPT1), LPL, ACC,
and FAS, in WT and p53 KO mice (B and C). On day 7, 2 hours after the last injection, mice were killed and tissues were collected and frozen at
80°C until further analysis. Values are mean  SEM of 7 to 8 animals per group. Two-way ANOVA followed by a Bonferroni’s post test was used
as statistical test. *, P  .05 **, P  .01.
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Overall, these results indicate that the brain p53 system
might be involved in the actions of ghrelin on liver and
WAT metabolism.
Discussion
Numerous reports indicate that pharmacological or ge-
netic manipulation of the ghrelin system affects adiposity
and body weight. Central and peripheral administration
of ghrelin increases adiposity and body weight gain (2, 3,
5). Consistent with this, elegant studies based on genetic
manipulations indicate that mice lacking ghrelin (31) or
ghrelin receptors (32) accumulate less fat mass than their
WT littermates when fed a high-fat diet. Moreover, abla-
tion of the ghrelin receptor reduces adiposity during aging
by regulating adipocyte metabolism (33). Although the
adipogenic action of this peptidic hormone is indubitable,
the molecular pathways by which ghrelin favors lipid de-
position remain largely unknown. Our current data dem-
onstrate that p53 is crucial for the adipogenic and lipo-
genic effect of ghrelin. These results appear to indicate that
a lack of p53 abolishes the stimulation of lipid storage
induced by chronically administered ghrelin in WAT and
liver.
Most effects mediated by ghrelin are exerted through
the GHS-R1a (34). GHS-R1a is widely expressed through-
out the central nervous system and in peripheral tissues
(35, 36), and although this receptor mediates both adipo-
genic and orexigenic actions of ghrelin, the mechanisms
controlling each process are different. The evidence for
this is that in DIO rats the hyperphagic effect of ghrelin
disappears (14, 15) even though the gain of adiposity re-
mains intact (14). It therefore seems likely that central and
peripheral pathways controlling ghrelin-induced feeding
behavior and adiposity are divergent. This hypothesis is
supported by our current data that under our experimen-
tal conditions chronic peripheral treatment with ghrelin
increased body weight gain and adiposity in WT mice,
without any alteration of food intake.
At the hypothalamic level, activation of GHS-R1a
causes a cellular response in which hypothalamic SIRT1 is
activated (20, 37) to deacetylate p53; this in turn leads to
increased phosphorylation of AMPK and subsequent in-
activation of the de novo fatty-acid biosynthetic pathway,
with concomitant activation of fatty-acid oxidation (28).
These molecular events induce changes in UCP2 and re-
active oxygen species (29), and up-regulation of the tran-
scription factors Bsx (38, 39), FoxO1, and pCREB (26).
The activation of these transcription factors leads to the
ultimate step that includes an increased transcription rate
of NPY and AgRP (40). Peripherally, however, studies
addressing the molecular mechanisms by which ghrelin
controls adipocyte metabolism are scarce. One in vitro
study has shown that ghrelin stimulates the activity of
glycerol-3-phosphate dehydrogenase in rat preadipocytes
and increases PPAR2 gene expression in primary cul-
tured differentiated adipocytes from rats (10). In vivo re-
ports demonstrate that ghrelin stimulates lipid deposition
in WAT and liver by increasing the expression and activity
of key enzymes involved in fatty acid metabolism, such as
SCD1, ACC, and FAS (3, 5). However, the molecular
events following activation of GHS-R1a but before mod-
ulation of enzymes involved in lipid metabolism remain
unknown.
Our in vivo observation that a lack of p53 abolishes the
lipogenic action of ghrelin in WAT and liver suggests that
this tumor suppressor is an important mediator of ghrelin
activity not only in the brain but also in peripheral tissues.
Interestingly, our in vivo study in p53-null mice shows that
in the absence of p53 ghrelin fails to stimulate the expres-
sion of genes responsible for 2 functions in WAT—those
that favor lipid uptake and deposition (SREBP1c, FAS,
LPL) and those that promote adipocyte differentiation
(PPAR, CEBP). Because the increased weight gain and
fat mass acquitted by WT ghrelin-treated mice failed to be
statistically significant when using a two-way ANOVA
test, it is likely that this discrepancy will disappear, in-
creasing the length of treatment. Our findings appear to
indicate that all the biochemical changes detected in WAT
Figure 4. Effect of a 7-day ip ghrelin injection (30 g/d) on
hypothalamic protein levels of phosphorylated AMP-activated protein
kinase (pAMPK), ACC, and FAS, in WT and p53 KO mice. On day 7, 2
hours after the last injection, mice were killed and tissues were
collected and frozen at 80°C until further analysis. Values are
mean  SEM of 7 to 8 animals per group. Two-way ANOVA followed
by a Bonferroni’s post test was used as statistical test. **, P  .01;
***, P  .001.
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and liver are likely preceding changes in fat mass and body
weight.
Another important question was whether these actions
of ghrelin on WAT and liver were mediated by the brain
p53 system. Although a chronic central ghrelin infusion
would address this question directly, unfortunately mice
lacking p53 did not withstand the surgery after several
days. Nevertheless, our findings support the hypothesis
that these actions might be modulated by the brain p53
system, because 1) our in vitro results indicate that adipose
tissue explants incubated at long term with ghrelin did not
show any alteration in the expression of lipogenic or adi-
pogenic genes, and 2) chronic peripheral treatment with
ghrelin decreased the hypothalamic protein levels of FAS,
which are downstream of p53 and AMPK (20, 28, 29).
It is also important to point out that WT and mice
lacking p53 fed a standard diet did not show differences in
body weight, food intake, or body composition. However,
they did show a significant increase in the expression of
enzymes modulating lipid metabolism in WAT (SREBP1
and LPL) and liver (ACC and FAS) as well as in hepatic
TG levels. These results partially agree with previous re-
ports indicating that p53 plays an important role in adi-
pose tissue (18, 19). Indeed, our findings might indicate
that body weight and fat mass of mice lacking p53 might
respond differentially to WT when they are challenged to
certain conditions such as high fat diet, but further studies
will be necessary to address this issue.
In summary, we demonstrate here that p53 is essential
for the peripheral actions of chronically administered
ghrelin on WAT and liver, because it regulates lipogenic
and adipogenic gene expression that lead ultimately to an
increase in body weight.
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